Article    Table of Contents                    Full Text of this article Free    PDF of this article    Figures/Tables List  Services    Send comment/rapid response letter    Notify a friend about this article    Alert me when this article is cited    Add to Personal Archive    Download to Citation Manager    ACP Search    Get Permissions  Google Scholar    Search for Related Content  Social Bookmarking

What's this?

PubMed

Articles in PubMed by Author:    Liang, T. J.    Hoofnagle, J. H.    Related Articles in PubMed    PubMed Citation    PubMed

NIH CONFERENCE

Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C

T. Jake Liang, MD Moderator: ; Barbara Rehermann, MD Discussants: ; Leonard B. Seeff, MD; and Jay H. Hoofnagle, MD

15 February 2000 | Volume 132 Issue 4 | Pages 296-305

Approximately 4 million persons in the United States and probably more than 100 million persons worldwide are infected with hepatitis C virus. The virus has the unique ability to cause persistent infection in susceptible hosts after parenteral or percutaneous transmission, and its underlying mechanisms are not well understood. The immunologic correlates of protection and viral clearance and the pathogenesis of liver injury are yet to be defined, but recent studies suggest the importance of cell-mediated immune responses. Although 70% to 80% of infected persons become chronic carriers, most have relatively mild disease with slow progression. However, chronic and progressive hepatitis C carries significant morbidity and mortality and is a major cause of cirrhosis, end-stage liver disease, and liver cancer. Development of an effective hepatitis C virus vaccine is not imminent, but recent advances in technology and basic knowledge of molecular virology and immunology have engendered novel approaches to the fundamental problems encountered in vaccine development. Current therapy for hepatitis C, although effective in some patients, is problematic and still evolving. Advances in modern biology and immunology promise new therapies for this important disease.

Author and Article Information

An edited summary of a Clinical Staff Conference held on 31 March 1999 at the National Institutes of Health in Bethesda, Maryland.

Authors who wish to cite a section of the conference and specifically indicate its author may use this example for the form of the reference: Rehermann B. Immunopathogenesis of hepatitis C. In: Liang TJ, moderator. Pathogenesis, natural history, treatment, and prevention of hepatitis C. Ann Intern Med. 2000; 132:297-299.

Requests for Single Reprints: T. Jake Liang, MD, Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Room 9B16, Bethesda, MD 20892-1800.

Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.

Current Author Addresses: Drs. Liang and Rehermann: Liver Diseases Section, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, 10 Center Drive, Room 9B16, Bethesda, MD 20892-1800.

Drs. Seeff and Hoofnagle: Division of Digestive Diseases and Nutrition, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Building 31, Room 9A23, Bethesda, MD 20892.

CiteULike

Complore

Connotea

Del.icio.us

Digg

Facebook

Reddit

Technorati

Twitter

This article has been cited by other articles:

				Y. J. Jeon, J. S. Choi, J. Y. Lee, K. R. Yu, S. H. Ka, Y. Cho, E.-J. Choi, S. H. Baek, J. H. Seol, D. Park, et al. Filamin B Serves as a Molecular Scaffold for Type I Interferon-induced c-Jun NH2-terminal Kinase Signaling Pathway Mol. Biol. Cell, December 1, 2008; 19(12): 5116 - 5130. [Abstract] [Full Text] [PDF]

				T. Masaki, R. Suzuki, K. Murakami, H. Aizaki, K. Ishii, A. Murayama, T. Date, Y. Matsuura, T. Miyamura, T. Wakita, et al. Interaction of Hepatitis C Virus Nonstructural Protein 5A with Core Protein Is Critical for the Production of Infectious Virus Particles J. Virol., August 15, 2008; 82(16): 7964 - 7976. [Abstract] [Full Text] [PDF]

				H. Ebinuma, N. Nakamoto, Y. Li, D. A. Price, E. Gostick, B. L. Levine, J. Tobias, W. W. Kwok, and K.-M. Chang Identification and In Vitro Expansion of Functional Antigen-Specific CD25+ FoxP3+ Regulatory T Cells in Hepatitis C Virus Infection J. Virol., May 15, 2008; 82(10): 5043 - 5053. [Abstract] [Full Text] [PDF]

				K Murao, H Imachi, X Yu, W M Cao, T Nishiuchi, K Chen, J Li, R A M Ahmed, N C W Wong, and T Ishida Interferon {alpha} decreases expression of human scavenger receptor class BI, a possible HCV receptor in hepatocytes Gut, May 1, 2008; 57(5): 664 - 671. [Abstract] [Full Text] [PDF]

				T. J. Liang Shortened Therapy for Hepatitis C Virus Genotype 2 or 3 -- Is Less More? N. Engl. J. Med., July 12, 2007; 357(2): 176 - 178. [Full Text] [PDF]

				G. A. Elmowalid, M. Qiao, S.-H. Jeong, B. B. Borg, T. F. Baumert, R. K. Sapp, Z. Hu, K. Murthy, and T. J. Liang Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees PNAS, May 15, 2007; 104(20): 8427 - 8432. [Abstract] [Full Text] [PDF]

				T. Kato, T. Matsumura, T. Heller, S. Saito, R. K. Sapp, K. Murthy, T. Wakita, and T. J. Liang Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures J. Virol., May 1, 2007; 81(9): 4405 - 4411. [Abstract] [Full Text] [PDF]

				A. A Butt, A. C Justice, M. Skanderson, M. O Rigsby, C. B Good, and C K. Kwoh Rate and predictors of treatment prescription for hepatitis C Gut, March 1, 2007; 56(3): 385 - 389. [Abstract] [Full Text] [PDF]

				Y. Huang, H. Yang, B. B. Borg, X. Su, S. L. Rhodes, K. Yang, X. Tong, G. Tang, C. D. Howell, H. R. Rosen, et al. A functional SNP of interferon-{gamma} gene is important for interferon-{alpha}-induced and spontaneous recovery from hepatitis C virus infection PNAS, January 16, 2007; 104(3): 985 - 990. [Abstract] [Full Text] [PDF]

				N. Dharel, N. Kato, R. Muroyama, M. Moriyama, R.-X. Shao, T. Kawabe, and M. Omata MDM2 Promoter SNP309 Is Associated with the Risk of Hepatocellular Carcinoma in Patients with Chronic Hepatitis C. Clin. Cancer Res., August 15, 2006; 12(16): 4867 - 4871. [Abstract] [Full Text] [PDF]

				D. Rincon, C. Ripoll, M. V. Catalina, M. Salcedo, and R. Banares Does interferon improve portal hypertension? J. Antimicrob. Chemother., July 1, 2006; 58(1): 7 - 12. [Abstract] [Full Text] [PDF]

				C. C. Crone, G. M. Gabriel, and A. DiMartini An Overview of Psychiatric Issues in Liver Disease for the Consultation-Liaison Psychiatrist Psychosomatics, June 1, 2006; 47(3): 188 - 205. [Abstract] [Full Text] [PDF]

				M Diago, G Castellano, J Garcia-Samaniego, C Perez, I Fernandez, M Romero, O L Iacono, and C Garcia-Monzon Association of pretreatment serum interferon {gamma} inducible protein 10 levels with sustained virological response to peginterferon plus ribavirin therapy in genotype 1 infected patients with chronic hepatitis C Gut, March 1, 2006; 55(3): 374 - 379. [Abstract] [Full Text] [PDF]

				T. Kato, T. Date, M. Miyamoto, M. Sugiyama, Y. Tanaka, E. Orito, T. Ohno, K. Sugihara, I. Hasegawa, K. Fujiwara, et al. Detection of Anti-Hepatitis C Virus Effects of Interferon and Ribavirin by a Sensitive Replicon System J. Clin. Microbiol., November 1, 2005; 43(11): 5679 - 5684. [Abstract] [Full Text] [PDF]

				C. E. Munoz-Plaza, S. M. Strauss, J. M. Astone, D. C. Des Jarlais, and H. Hagan Hepatitis C Service Delivery in Prisons: Peer Education From the "Guys in Blue" Journal of Correctional Health Care, July 1, 2005; 11(4): 347 - 368. [Abstract] [PDF]

				K. Sugimoto, D. E. Kaplan, F. Ikeda, J. Ding, J. Schwartz, F. A. Nunes, H. J. Alter, and K.-M. Chang Strain-Specific T-Cell Suppression and Protective Immunity in Patients with Chronic Hepatitis C Virus Infection J. Virol., June 1, 2005; 79(11): 6976 - 6983. [Abstract] [Full Text] [PDF]

				S M Kamal, A A El Tawil, T Nakano, Q He, J Rasenack, S A Hakam, W A Saleh, A Ismail, A A Aziz, and M A. Madwar Peginterferon {alpha}-2b and ribavirin therapy in chronic hepatitis C genotype 4: impact of treatment duration and viral kinetics on sustained virological response Gut, June 1, 2005; 54(6): 858 - 866. [Abstract] [Full Text] [PDF]

				H. Zheng, P. Hu, D. F. Quinn, and Y. K. Wang Phosphotyrosine Proteomic Study of Interferon {alpha} Signaling Pathway Using a Combination of Immunoprecipitation and Immobilized Metal Affinity Chromatography Mol. Cell. Proteomics, June 1, 2005; 4(6): 721 - 730. [Abstract] [Full Text] [PDF]

				M. Amacker, O. Engler, A. R. Kammer, S. Vadrucci, D. Oberholzer, A. Cerny, and R. Zurbriggen Peptide-loaded chimeric influenza virosomes for efficient in vivo induction of cytotoxic T cells Int. Immunol., June 1, 2005; 17(6): 695 - 704. [Abstract] [Full Text] [PDF]

				V Lo Re III and J R Kostman Management of chronic hepatitis C Postgrad. Med. J., June 1, 2005; 81(956): 376 - 382. [Abstract] [Full Text] [PDF]

				H. Barth, A. Ulsenheimer, G. R. Pape, H. M. Diepolder, M. Hoffmann, C. Neumann-Haefelin, R. Thimme, P. Henneke, R. Klein, G. Paranhos-Baccala, et al. Uptake and presentation of hepatitis C virus-like particles by human dendritic cells Blood, May 1, 2005; 105(9): 3605 - 3614. [Abstract] [Full Text] [PDF]

				H. Dutartre, J. Boretto, J. C. Guillemot, and B. Canard A Relaxed Discrimination of 2'-O-Methyl-GTP Relative to GTP between de Novo and Elongative RNA Synthesis by the Hepatitis C RNA-dependent RNA Polymerase NS5B J. Biol. Chem., February 25, 2005; 280(8): 6359 - 6368. [Abstract] [Full Text] [PDF]

				T. Heller, S. Saito, J. Auerbach, T. Williams, T. R. Moreen, A. Jazwinski, B. Cruz, N. Jeurkar, R. Sapp, G. Luo, et al. An in vitro model of hepatitis C virion production PNAS, February 15, 2005; 102(7): 2579 - 2583. [Abstract] [Full Text] [PDF]

				A. Y. M. Howe, J. Bloom, C. J. Baldick, C. A. Benetatos, H. Cheng, J. S. Christensen, S. K. Chunduru, G. A. Coburn, B. Feld, A. Gopalsamy, et al. Novel Nonnucleoside Inhibitor of Hepatitis C Virus RNA-Dependent RNA Polymerase Antimicrob. Agents Chemother., December 1, 2004; 48(12): 4813 - 4821. [Abstract] [Full Text] [PDF]

				S. Einav, M. Elazar, T. Danieli, and J. S. Glenn A Nucleotide Binding Motif in Hepatitis C Virus (HCV) NS4B Mediates HCV RNA Replication J. Virol., October 15, 2004; 78(20): 11288 - 11295. [Abstract] [Full Text] [PDF]

				M. Elazar, P. Liu, C. M. Rice, and J. S. Glenn An N-Terminal Amphipathic Helix in Hepatitis C Virus (HCV) NS4B Mediates Membrane Association, Correct Localization of Replication Complex Proteins, and HCV RNA Replication J. Virol., October 15, 2004; 78(20): 11393 - 11400. [Abstract] [Full Text] [PDF]

				D. Steinmann, H. Barth, B. Gissler, P. Schurmann, M. I. Adah, J. T. Gerlach, G. R. Pape, E. Depla, D. Jacobs, G. Maertens, et al. Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C J. Virol., September 1, 2004; 78(17): 9030 - 9040. [Abstract] [Full Text] [PDF]

				D.-R. Hwang, Y.-C. Tsai, J.-C. Lee, K.-K. Huang, R.-K. Lin, C.-H. Ho, J.-M. Chiou, Y.-T. Lin, J. T. A. Hsu, and C.-T. Yeh Inhibition of Hepatitis C Virus Replication by Arsenic Trioxide Antimicrob. Agents Chemother., August 1, 2004; 48(8): 2876 - 2882. [Abstract] [Full Text] [PDF]

				C. de Lalla, G. Galli, L. Aldrighetti, R. Romeo, M. Mariani, A. Monno, S. Nuti, M. Colombo, F. Callea, S. A. Porcelli, et al. Production of Profibrotic Cytokines by Invariant NKT Cells Characterizes Cirrhosis Progression in Chronic Viral Hepatitis J. Immunol., July 15, 2004; 173(2): 1417 - 1425. [Abstract] [Full Text] [PDF]

				S.-H. Jeong, M. Qiao, M. Nascimbeni, Z. Hu, B. Rehermann, K. Murthy, and T. J. Liang Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates J. Virol., July 1, 2004; 78(13): 6995 - 7003. [Abstract] [Full Text] [PDF]

				M. J. Cunningham, E. A. Macklin, E. J. Neufeld, A. R. Cohen, and the Thalassemia Clinical Research Network Complications of {beta}-thalassemia major in North America Blood, July 1, 2004; 104(1): 34 - 39. [Abstract] [Full Text] [PDF]

				Y. Nakamoto, T. Suda, T. Momoi, and S. Kaneko Different Procarcinogenic Potentials of Lymphocyte Subsets in a Transgenic Mouse Model of Chronic Hepatitis B Cancer Res., May 1, 2004; 64(9): 3326 - 3333. [Abstract] [Full Text] [PDF]

				K. J. Lee, J. Choi, J.-h. Ou, and M. M. C. Lai The C-Terminal Transmembrane Domain of Hepatitis C Virus (HCV) RNA Polymerase Is Essential for HCV Replication In Vivo J. Virol., April 1, 2004; 78(7): 3797 - 3802. [Abstract] [Full Text] [PDF]

				S. Castellino, S. Lensing, C. Riely, S. N. Rai, R. Davila, R. T. Hayden, J. Fleckenstein, M. Levstik, S. Taylor, P. J. Dean, et al. The epidemiology of chronic hepatitis C infection in survivors of childhood cancer: an update of the St Jude Children's Research Hospital hepatitis C seropositive cohort Blood, April 1, 2004; 103(7): 2460 - 2466. [Abstract] [Full Text] [PDF]

				L. G. Rocca, B. P. Yawn, P. Wollan, and W. R. Kim Management of Patients With Hepatitis C in a Community Population: Diagnosis, Discussions, and Decisions to Treat Ann. Fam. Med, March 1, 2004; 2(2): 116 - 124. [Abstract] [Full Text] [PDF]

				C. Rollier, E. Depla, J. A. R. Drexhage, E. J. Verschoor, B. E. Verstrepen, A. Fatmi, C. Brinster, A. Fournillier, J. A. Whelan, M. Whelan, et al. Control of Heterologous Hepatitis C Virus Infection in Chimpanzees Is Associated with the Quality of Vaccine-Induced Peripheral T-Helper Immune Response J. Virol., January 1, 2004; 78(1): 187 - 196. [Abstract] [Full Text] [PDF]

				M. Jinushi, T. Takehara, T. Tatsumi, T. Kanto, V. Groh, T. Spies, T. Suzuki, T. Miyagi, and N. Hayashi Autocrine/Paracrine IL-15 That Is Required for Type I IFN-Mediated Dendritic Cell Expression of MHC Class I-Related Chain A and B Is Impaired in Hepatitis C Virus Infection J. Immunol., November 15, 2003; 171(10): 5423 - 5429. [Abstract] [Full Text] [PDF]

				D. K. Henderson Managing Occupational Risks for Hepatitis C Transmission in the Health Care Setting Clin. Microbiol. Rev., July 1, 2003; 16(3): 546 - 568. [Abstract] [Full Text] [PDF]

				K. Murata, M. Lechmann, M. Qiao, T. Gunji, H. J. Alter, and T. J. Liang Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection PNAS, May 27, 2003; 100(11): 6753 - 6758. [Abstract] [Full Text] [PDF]

				M. Elazar, K. H. Cheong, P. Liu, H. B. Greenberg, C. M. Rice, and J. S. Glenn Amphipathic Helix-Dependent Localization of NS5A Mediates Hepatitis C Virus RNA Replication J. Virol., May 15, 2003; 77(10): 6055 - 6061. [Abstract] [Full Text] [PDF]

				H. Zhu and C. Liu Interleukin-1 Inhibits Hepatitis C Virus Subgenomic RNA Replication by Activation of Extracellular Regulated Kinase Pathway J. Virol., May 1, 2003; 77(9): 5493 - 5498. [Abstract] [Full Text] [PDF]

				U Siebert, G Sroczynski, S Rossol, J Wasem, U Ravens-Sieberer, B M Kurth, M P Manns, J G McHutchison, and J B Wong Cost effectiveness of peginterferon {alpha}-2b plus ribavirin versus interferon {alpha}-2b plus ribavirin for initial treatment of chronic hepatitis C Gut, March 1, 2003; 52(3): 425 - 432. [Abstract] [Full Text] [PDF]

				S. H. Dinwiddie, L. Shicker, and T. Newman Prevalence of Hepatitis C Among Psychiatric Patients in the Public Sector Am J Psychiatry, January 1, 2003; 160(1): 172 - 174. [Abstract] [Full Text] [PDF]

				H. Kojima, K. D. E. Kaita, K. Hawkins, J. Uhanova, and G. Y. Minuk Use of Fluoroquinolones in Patients with Chronic Hepatitis C Virus-Induced Liver Failure Antimicrob. Agents Chemother., October 1, 2002; 46(10): 3280 - 3282. [Abstract] [Full Text] [PDF]

				V. Castet, C. Fournier, A. Soulier, R. Brillet, J. Coste, D. Larrey, D. Dhumeaux, P. Maurel, and J.-M. Pawlotsky Alpha Interferon Inhibits Hepatitis C Virus Replication in Primary Human Hepatocytes Infected In Vitro J. Virol., July 17, 2002; 76(16): 8189 - 8199. [Abstract] [Full Text] [PDF]

				S. K. Herrine Approach to the Patient with Chronic Hepatitis C Virus Infection Ann Intern Med, May 21, 2002; 136(10): 747 - 757. [Abstract] [Full Text] [PDF]

				S. Wellnitz, B. Klumpp, H. Barth, S. Ito, E. Depla, J. Dubuisson, H. E. Blum, and T. F. Baumert Binding of Hepatitis C Virus-Like Particles Derived from Infectious Clone H77C to Defined Human Cell Lines J. Virol., February 1, 2002; 76(3): 1181 - 1193. [Abstract] [Full Text] [PDF]

				N. Pavio, D. R. Taylor, and M. M. C. Lai Detection of a Novel Unglycosylated Form of Hepatitis C Virus E2 Envelope Protein That Is Located in the Cytosol and Interacts with PKR J. Virol., February 1, 2002; 76(3): 1265 - 1272. [Abstract] [Full Text] [PDF]

				E. R. Quinn, C. H. Chan, K. G. Hadlock, S. K. H. Foung, M. Flint, and S. Levy The B-cell receptor of a hepatitis C virus (HCV)-associated non-Hodgkin lymphoma binds the viral E2 envelope protein, implicating HCV in lymphomagenesis Blood, December 15, 2001; 98(13): 3745 - 3749. [Abstract] [Full Text] [PDF]

				J. H. Hoofnagle Therapy for Acute Hepatitis C N. Engl. J. Med., November 15, 2001; 345(20): 1495 - 1497. [Full Text] [PDF]

				M. Franchini, G. Rossetti, A. Tagliaferri, F. Capra, E. de Maria, C. Pattacini, G. Lippi, G. Lo Cascio, M. de Gironcoli, and G. Gandini The natural history of chronic hepatitis C in a cohort of HIV-negative Italian patients with hereditary bleeding disorders Blood, September 15, 2001; 98(6): 1836 - 1841. [Abstract] [Full Text] [PDF]

				I Nakano, Y Fukuda, Y Katano, H Toyoda, K Hayashi, T Hayakawa, T Kumada, and S Nakano Interferon responsiveness in patients infected with hepatitis C virus 1b differs depending on viral subtype Gut, August 1, 2001; 49(2): 263 - 267. [Abstract] [Full Text] [PDF]

				B. R. Edlin, K. H. Seal, J. Lorvick, A. H. Kral, D. H. Ciccarone, L. D. Moore, and B. Lo Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users? N. Engl. J. Med., July 19, 2001; 345(3): 211 - 214. [Full Text] [PDF]

				S. J. Polyak, K. S. A. Khabar, D. M. Paschal, H. J. Ezelle, G. Duverlie, G. N. Barber, D. E. Levy, N. Mukaida, and D. R. Gretch Hepatitis C Virus Nonstructural 5A Protein Induces Interleukin-8, Leading to Partial Inhibition of the Interferon-Induced Antiviral Response J. Virol., July 1, 2001; 75(13): 6095 - 6106. [Abstract] [Full Text] [PDF]

				S. J. Polyak, K. S. A. Khabar, M. Rezeiq, and D. R. Gretch Elevated Levels of Interleukin-8 in Serum Are Associated with Hepatitis C Virus Infection and Resistance to Interferon Therapy J. Virol., July 1, 2001; 75(13): 6209 - 6211. [Abstract] [Full Text] [PDF]

				S. Auffermann-Gretzinger, E. B. Keeffe, and S. Levy Impaired dendritic cell maturation in patients with chronic, but not resolved, hepatitis C virus infection Blood, May 15, 2001; 97(10): 3171 - 3176. [Abstract] [Full Text] [PDF]

				C. H. Chan, K. G. Hadlock, S. K. H. Foung, and S. Levy VH1-69 gene is preferentially used by hepatitis C virus-associated B cell lymphomas and by normal B cells responding to the E2 viral antigen Blood, February 15, 2001; 97(4): 1023 - 1026. [Abstract] [Full Text] [PDF]

				A. J. Behrman, D. L. Thomas, S. A. Strathdee, and D. Vlahov Long-term Prognosis of Hepatitis C Virus Infection JAMA, November 22, 2000; 284(20): 2592 - 2592. [Full Text] [PDF]

				J. G. Bartlett Update in Infectious Diseases Ann Intern Med, August 15, 2000; 133(4): 285 - 292. [Full Text] [PDF]